Harshada Sant, MS

Tara Innovations LLC

Articles by Harshada Sant, MS

  • HORIZON LINES: A Quarterly Review of NDAs – 2Q16

    Sunday, November 20, 2016
    This column summarizes New Drug Applications (NDAs) approved in the second quarter 2016 (May-June 2016). In this quarter, FDA approved 23 NDAs.
  • HORIZON LINES A Review of NDAs for January-February, 2016

    Friday, September 30, 2016
    This column summarizes New Drug Applications (NDAs) for January-February, 2016. In these two months, FDA approved 25 NDAs.
  • Horizon Lines: A Yearly Review of NDAs - 2015

    Thursday, July 21, 2016
    For decades, the regulation and control of new drugs in the United States has been based on the New Drug Application (NDA). Since 1938, every new drug has been the subject of an approved NDA before U.S. commercialization. This column summarizes ...
  • HORIZON LINES: A Quarterly Review of NDAs – 4Q15

    Monday, May 30, 2016
    This column summarizes New Drug Applications (NDAs) approved in the fourth quarter 2015 (November-December 2015). In these two months, FDA approved 30 NDAs.
  • HORIZON LINES: A Quarterly Review of NDAs – 3Q15

    Thursday, March 31, 2016
    Twenty-five (65.8%) NDAs were for small molecules while the remaining 13 (34.2%) were for large molecules. Most of the large molecules were used in the cancer therapy. In this quarter, 18 companies (47.4%) receiving NDA approvals were large ...
  • HORIZON LINES: A Quarterly Review of NDAs May-July, 2015

    Sunday, January 31, 2016
    This column summarizes New Drug Applications (NDAs) from May 2015 to July 2015. In this quarter, FDA approved 26 NDAs.
  • HORIZON LINES: A Review of NDAs – March-April, 2015

    Monday, November 30, 2015
    This column summarizes New Drug Applications (NDAs) for March and April 2015. In these two months, FDA approved 25 NDAs.
  • A Review of NDAs – January-February 2015

    Wednesday, September 30, 2015
    Twenty one (75 %) NDA’s were for small molecules while the remaining seven molecules (25%) were large molecules. Ferric pyrophosphate citrate (Triferic), from its name, does not seem to be a typical large molecule. It was considered as a large ...
  • HORIZON LINES: A Yearly Review of NDAs – 2014

    Friday, July 31, 2015
    A total of 133 NDAs were approved in 2014. This column summarizes details on all the NDAs (New Drug Applications) approved in 2014. The details on individual NDAs can be obtained from the articles listed in the reference section.
  • HORIZON LINES: A Quarterly Review of NDAs - 4Q14

    Thursday, May 28, 2015
    This column summarizes New Drug Applications (NDAs) for the Fourth quarter 2014 (October through December 2014). In this quarter, FDA approved 46 NDAs.
Page